17B$ = BCG market as standard treatment of careThis is what is compelling to big pharma; the possibility to also displace BCG in early-stage setting of NMIBC, now that we have demonstrated high CR % @90-days and long duration DR %. Not just in BCG-Unresponsive.
That would represent a market opportunity of 17B$US/year. That's
170,000 patients treated each year with BCG as standard treatment of care (as per p. 6 of TLT's presentation) x 100,000$US/treatment.
You bet that a big pharma would do everything to advance TLD1433 in the early-stage setting and displace BCG as the SOC (standard of care).
Again, we have high efficacy %s. And no need to have 16+ treatments.
Compelling to patients. Amazing business opportunity for a big pharma to reap major market shares.
We get Accelerated Approval and a jv follows.
https://theralase.com/wp-content/uploads/2022/07/Presentation-2022.pdf